Table 3 Dosing scheme per product used in the analysis
From: Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece
Agent | Dosing scheme |
|---|---|
Adalimumab | 80 mg at week 0, 40 mg at week 1, then 40 mg every other week |
Etanercept | 50 mg twice weekly for 12 weeks, then 50 mg once weekly |
Infliximab | 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks |
Ustekinumab | 45 mg at weeks 0 and 4, then every 12 weeks |